Erratum: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium (Investigational New Drugs DOI: 10.1007/s10637-010-9420-8);Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: A randomized phase II trial by the prostate cancer clinical trials consortium

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1432-1440

  Bradley, Deborah A ^a   Daignault, Stephanie ^b   Ryan, Charles J ^c   DiPaola, Robert S ^d   Smith, David C ^b   Small, Eric ^c   Gross, Mitchell E ^e   Stein, Mark N ^d   Chen, Alice ^f   Hussain, Maha ^b,g  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Angiogenesis; Bone biomarkers; Cilengitide; Integrins; Metastatic disease; Prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ALPHAVBETA5 INTEGRIN; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; CILENGITIDE; NSC 707544; OSTEOCALCIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; SNAKE VENOM;

ADULT; AGED; ANOREXIA; ARTHRITIS; ARTICLE; ASYMPTOMATIC DISEASE; BONE PAIN; CANCER CHEMOTHERAPY; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DEHYDRATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; LEUKOPENIA; LIMB PAIN; LYMPH NODE PAIN; LYMPHATIC SYSTEM DISEASE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STUDY DESIGN; TOOTH INFECTION; TREATMENT DURATION; TUMOR GROWTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; FOLLOW UP; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TIME; TREATMENT OUTCOME; TUMOR EMBOLISM;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENTS; COLLAGEN TYPE I; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SNAKE VENOMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84856025302     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9502-7     Document Type: Erratum

References (50)

1. EMD 121974 Cilengitide, cyclo-[Arg-Gly-Asp-DPhe-(NMeVal)]. Investigator's Brochure
2. Albelda SM (1993) Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 68:4-17 (Pubitemid 23055008)
3. Allen MV, Smith GJ, Juliano R, Maygarden SJ, Mohler JL (1998) Downregulation of the beta4 integrin subunit in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol 29:311-318 (Pubitemid 28231893)
4. Assoian RK, Schwartz MA (2001) Coordinate signaling by integrins and receptor tyrosine kinases in the regulation of G1 phase cell-cycle progression. Curr Opin Genet Dev 11:48-53 (Pubitemid 32119277)
5. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
6. Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, Lee KA, Zheng M, Hei YJ, Coleman RE (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59-69
7. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G et al (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group. J Clin Oncol 17:3461-3467 (Pubitemid 29517916)
8. Carducci M, Nelson JB, Saad F, Schulman CC, Dearnaley DP, Sleep DJ, Hulting SM, Isaacson JD, Allen A, Nisen P (2004) Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: phase 3 study. J Clin Oncol 22:4508
9. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21:679-689 (Pubitemid 46621903)
10. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD, Nelson JB (2007) A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110:1959-1966 (Pubitemid 350036854)
11. Coleman RE, Major P, Lipton A, Brown JE, Lee KA, Smith M, Saad F, Zheng M, Hei YJ, Seaman J, Cook R (2005) Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 23:4925-4935 (Pubitemid 46223998)
12. Cooper CR, Chay CH, Pienta KJ (2002) The role of alpha (v) beta (3) in prostate cancer progression. Neoplasia 4:191-194 (Pubitemid 34525250)
13. Cooper CR, Pienta KJ (2000) Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis 3:6-12 (Pubitemid 30616513)
14. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053-7058 (Pubitemid 350276887)
15. Davis TL, Cress AE, Dalkin BL, Nagle RB (2001) Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate 46:240-248 (Pubitemid 32142771)
16. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 14:6302-6309
17. Duong LT, Lakkakorpi P, Nakamura I, Rodan GA (2000) Integrins and signaling in osteoclast function. Matrix Biol 19:97-105 (Pubitemid 30332433)
18. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917-926 (Pubitemid 36428623)
19. Fornaro M, Manes T, Languino LR (2001) Integrins and prostate cancer metastases. Cancer Metastasis Rev 20:321-331 (Pubitemid 34595274)
20. Hariharan S, Gustafson D, Holden S, McConkey D, Davis D, Morrow M, Basche M, Gore L, Zang C, O'Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG (2007) Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18:1400-1407 (Pubitemid 47305015)
21. Holly SP, Larson MK, Parise LV (2000) Multiple roles of integrins in cell motility. Exp Cell Res 261:69-74
22. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100 (Pubitemid 37328796)
23. Hughes DE, Salter DM, Dedhar S, Simpson R (1993) Integrin expression in human bone. J Bone Miner Res 8:527-533 (Pubitemid 23127912)
24. Keller ET, Brown J (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91:718-729
25. Knox JD, Cress AE, Clark V, Manriquez L, Affinito KS, Dalkin BL, Nagle RB (1994) Differential expression of extracellular matrix molecules and the alpha 6-integrins in the normal and neoplastic prostate. Am J Pathol 145:167-174
26. Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR (2006) A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12:1556-1563
27. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 113:193-201 (Pubitemid 351976401)
28. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012. J Clin Oncol 26:919-924 (Pubitemid 351398085)
29. Moreno J, DeBono JS, Shaffer D, Montgomery B, Miller MC, Tissing H, Doyle G, Terstappen LW, Pienta KJ, Raghavan D (2007) Multi-center study evaluating circulating tumor cells (CTCs) as a surrogate for survival in men treated for castration refractory prostate cancer (CRPC). J Clin Oncol 25: abstract 5016
30. Moreno JG, Miller MC, Gross S, Allard WJ, Gomella LG, Terstappen LW (2005) Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology 65:713-718 (Pubitemid 40523005)
31. Murant SJ, Handley J, Stower M, Reid N, Cussenot O, Maitland NJ (1997) Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33:263-271
32. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25:1651-1657 (Pubitemid 46797943)
33. Nagle RB, Knox JD, Wolf C, Bowden GT, Cress AE (1994) Adhesion molecules, extracellular matrix, and proteases in prostate carcinoma. J Cell Biochem Suppl 19:232-237 (Pubitemid 24306473)
34. Nakamura I, Pilkington MF, Lakkakorpi PT, Lipfert L, Sims SM, Dixon SJ, Rodan GA, Duong LT (1999) Role of alpha (v) beta (3) integrin in osteoclast migration and formation of the sealing zone. J Cell Sci 112(Pt 22):3985-3993 (Pubitemid 30119768)
35. Nemeth JA, Cher ML, Zhou Z, Mullins C, Bhagat S, Trikha M (2003) Inhibition of alpha (v) beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases. Clin Exp Metastasis 20:413-420 (Pubitemid 37108427)
36. Pidgeon GP, Tang K, Cai YL, Piasentin E, Honn KV (2003) Overexpression of platelet-type 12-lipoxygenase promotes tumor cell survival by enhancing alpha (v) beta (3) and alpha (v) beta (5) integrin expression. Cancer Res 63:4258-4267 (Pubitemid 36917955)
37. Reardon D, Fink K, Nabors B, Cloughesy T, Plotkin S, Schiff D, Raizer J, Krueger S, Picard M, Mikkelsen T (2007) Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009. J Clin Oncol 25: abstract 2002
38. Rodan SB, Rodan GA (1997) Integrin function in osteoclasts. J Endocrinol 154 (Suppl): S47-S56
39. Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, Connelly MC, Rao C, Terstappen LW (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71:105-113 (Pubitemid 46238939)
40. Ruoslahti E, Reed JC (1994) Anchorage dependence, integrins, and apoptosis. Cell 77:477-478 (Pubitemid 24153987)
41. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468
42. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26:1148-1159
43. Schmelz M, Cress AE, Scott KM, Burger F, Cui H, Sallam K, McDaniel KM, Dalkin BL, Nagle RB (2002) Different phenotypes in human prostate cancer: alpha6 or alpha3 integrin in cellextracellular adhesion sites. Neoplasia 4:243-254 (Pubitemid 34525256)
44. Shah RB, Mehra R, Chinnaiyan AM, Shen R, Ghosh D, Zhou M, Macvicar GR, Varambally S, Harwood J, Bismar TA, Kim R, Rubin MA, Pienta KJ (2004) Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res 64:9209-9216 (Pubitemid 39665537)
45. Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375-1381 (Pubitemid 16163075)
46. Slack-Davis JK, Parsons JT (2004) Emerging views of integrin signaling: implications for prostate cancer. J Cell Biochem 91:41-46
47. Stewart DA, Cooper CR, Sikes RA (2004) Changes in extracellular matrix (ECM) and ECM-associated proteins in the metastatic progression of prostate cancer. Reprod Biol Endocrinol 2:2
48. Tantivejkul K, Kalikin LM, Pienta KJ (2004) Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91:706-717
49. Vogelzang N, Nelson J, Schulman C, Dearnaley D, Saad F, Sleep D, Isaacson J, Carducci M (2005) Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. J Clin Oncol 23:4563
50. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR (1999) Prostatic carcinoma cell migration via alpha (v) beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-1664 (Pubitemid 29160140)